UK's national HPV vaccination programme extended

The UK's national vaccination programme against HPV is being extended to offer protection to an additional 300,000 girls aged 17-18, starting in September, Public Health Minister Dawn Primarolo announced today.

This is in addition to the routine vaccination of girls 12-13 years old which starts this September and will save up to 400 lives for each year of girls receiving the vaccine.

This extension was made possible thanks to the considerable savings that were achieved through the negotiation of the vaccine procurement process. The extension of the programme will use the same vaccine - 'Cervarix' - which is produced by pharmaceutical company GlaxoSmithKline.

A two year 'catch-up programme' will start in the school year 2009/10 to vaccinate girls aged between 15 to 18. Today's announcement means that girls, who would not otherwise have been included in this catch-up programme, will now be vaccinated this school year.

Public Health Minister Dawn Primarolo said:

"Our policy to vaccinate girls against cervical cancer is one of the biggest public health campaigns in recent history. It will mean that up to 400 girls' lives will be saved each year.

"By choosing the right vaccine we have been able to make savings which means we can extend the programme to 17 and 18 year olds. This could save an additional 400 lives."

The vaccine will guard against the two strains of the HPV virus which cause 70% of cases of cervical cancer, the second most common cancer in women worldwide. The original catch up programme will be delivered to girls up to 18 years from September 2009.

The Department of Health will provide additional support to PCTs in guidance and funding to ensure that the roll out of the older cohort is a success. There will be an additional £10 million for PCTs in the 2008/09 financial year to implement this extra programme.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths